Si Sun

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

The diversity and breadth of cancer cell fatty acid metabolism

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data

Engineering precision nanoparticles for drug delivery

Breast cancer

Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application

Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review

Novel polymeric micelles for drug delivery: Material characterization and formulation screening

Macrophages in immunoregulation and therapeutics

New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

Colorectal cancer

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

Platinum-based drugs: past, present and future

Tumour-associated macrophages as treatment targets in oncology

Cisplatin: The first metal based anticancer drug

The PI3K Pathway in Human Disease

Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions

Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Aloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells

Combination therapy in combating cancer

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

Autophagy mediates free fatty acid effects on MDA-MB-231 cell proliferation, migration and invasion

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Chalcone Derivatives: Role in Anticancer Therapy

Polymer nanoparticle delivery of dichloroacetate and DACH-Pt to enhance antitumor efficacy and lower systemic toxicity

Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen

Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors